Regulatory compliance
The TGA monitors and enforces regulatory compliance in relation to therapeutic goods. This supports consumer protection and a fair market for industry.
Latest alerts
- EVE Allylisopropylacetylurea tabletsThe TGA is warning consumers against taking EVE branded products that contain allylisopropylacetylurea (apronal) as they pose a significant health risk and are prohibited from sale, supply or use in Australia.
- Counterfeit semaglutide vialsThe TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.
Latest articles
- TGA seizes 40,000 vapes as part of multi-agency operation in QueenslandOn 29 August 2023, the TGA executed multiple warrants on storage units and residences in Brisbane and seized over 40,000 vaping products with an estimated street value of over $1.2 million
- Post-market review of facemasks closedThe COVID-19 pandemic post-market review of facemasks is now finished.
- Nius Development Pty Ltd fined $26,640 for allegedly importing unapproved cosmetic injectable productsWe have issued infringement notices for $26,640 to Nius Development Pty Ltd for the alleged unlawful import of unapproved cosmetic injectable products.
Latest publications
- Therapeutic goods advertising compliance: 2022-23 Annual ReportOverview of therapeutic goods advertising complaints handling and compliance for 2022-23
- Therapeutic Goods Advertising and Compliance Education Plan 2023This plan outlines the compliance and education priorities of the Therapeutic Goods Administration for 2023.
- Therapeutic goods advertising compliance: 2021-22 Annual ReportOverview of therapeutic goods advertising complaints handling and compliance for 2021-22